Cumberland and Clinigen enter Totect US commercialization pact

US specialty firm Cumberland Pharmaceuticals (Nasdaq: CPIX) has entered into an exclusive agreement to commercialize the oncology support drug Totect (dexrazoxane hydrochloride) in the USA with UK-based Clinigen Group (AIM: CLIN).

This is the second product pharmaceuticals and services company Clinigen has licensed to Cumberland under the strategic alliance established in 2015, following the launch of Ethyol (amifostine) in the USA in September 2016. Financial terms of the collaboration have not been disclosed.

Totect is a US Food and Drug Administration-approved emergency oncology intervention, which is indicated to reverse the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body causing severe damage and serious complications. Totect can reverse such damage without the need for additional surgeries and procedures, enabling patients to continue their essential anti-cancer treatment.